MARVIN TURCK, M.D.; KENNETH N. ANDERSON, M.D.; RONALD H. SMITH, M.D; JAMES F. WALLACE, M.D.; ROBERT G. PETERSDORF, M.D., F.A.C.P.
Cephalothin, 7 (thiophene-2-acetamido)-cephalosporanic acid, is a semisynthetic derivative of cephalosporin C. Although the structures of the cephalothin nucleus (7-amino-cephalosporanic acid) and the penicillin nucleus (6-amino-penicillanic acid) are quite similar, there are numerous differences in the biologic behavior of these drugs, including apparent lack of cross allergenicity, resistance of cephalothin to degradation by penicillinase, and cephalothin's broader antimicrobial spectrum (1-7). Results of preliminary studies conducted in our laboratories in 1962 (8) suggested that cephalothin might be useful in diverse systemic infections and prompted further clinical trials. The present report is an extension of these original in vitro and in vivo observations
MARVIN TURCK, KENNETH N. ANDERSON, RONALD H. SMITH, JAMES F. WALLACE, ROBERT G. PETERSDORF. Laboratory and Clinical Evaluation of a New Antibiotic—Cephalothin. Ann Intern Med. 1965;63:199–211. doi: 10.7326/0003-4819-63-2-199
Download citation file:
Published: Ann Intern Med. 1965;63(2):199-211.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use